​

Cue Biopharma (CUE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CUE Stock Forecast

Cue Biopharma (CUE) stock forecast, based on 3 Wall Street analysts, predicts a 12-month average price target of $4.00, with a high of $4.00 and a low of $4.00. This represents a 198.51% increase from the last price of $1.34.

High: $4 Avg: $4 Low: $4 Last Closed Price: $1.34

CUE Stock Rating

Cue Biopharma stock's rating consensus is Buy, based on 3 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 3 0 3 Strong Sell Sell Hold Buy Strong Buy

CUE Forecast vs Benchmarks

TypeNameUpside
StockCue Biopharma198.51%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-13
Avg Price Target-$4.00$4.00
Last Closing Price$1.34$1.34$1.34
Upside/Downside-198.51%198.51%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2523---5
Dec, 2423---5
Nov, 2423---5
Oct, 2433---6
Sep, 2433---6
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 15, 2024Maury RaycroftJefferies$4.00$1.29210.08%198.51%
Jul 26, 2024Reni BenjaminJMP Securities$2.00$0.70185.71%49.25%
Mar 13, 2024Maury RaycroftJefferies$6.00$2.15179.07%347.76%
Nov 20, 2022Edward TenthoffPiper Sandler$7.00$3.22117.39%422.39%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Nov 15, 2024JefferiesBuyBuyhold
Jul 26, 2024Piper SandlerOverweightOverweighthold
Jul 26, 2024JMP SecuritiesOutperformOutperformhold
Apr 09, 2024OppenheimerUnderperformUnderperformhold
Nov 20, 2022Piper SandlerOverweightinitialise

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.56$-1.41$-1.48$-1.11-----
Avg Forecast$-1.52$-1.54$-1.35$-1.20$-0.74$-0.52$-0.42$-0.46$-0.24
High Forecast$-3.57$-3.62$-2.28$-1.30$-0.79$-0.62$-0.53$-0.56$-0.48
Low Forecast$-0.32$-0.32$-0.80$-1.10$-0.69$-0.38$-0.21$-0.40$-0.11
Surprise %2.63%-8.44%9.63%-7.50%-----

Revenue Forecast

$0 $18M $36M $54M $72M $90M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.15M$14.94M$1.25M$5.49M-----
Avg Forecast$3.83M$7.57M$1.20M$3.63M$9.41M$10.45M$19.02M$19.49M$48.84M
High Forecast$1.51M$2.98M$821.74K$1.40M$8.10M$6.20M$11.28M$11.56M$28.97M
Low Forecast$7.83M$15.46M$1.83M$5.32M$10.40M$18.39M$33.48M$34.32M$85.99M
Surprise %-17.70%97.48%3.96%51.05%-----

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-44.78M$-44.16M$-52.80M$-50.73M-----
Avg Forecast$-69.37M$-70.31M$-61.88M$-50.73M$-33.90M$-22.80M$-16.83M$-21.98M$-11.13M
High Forecast$-163.50M$-165.70M$-104.26M$-59.43M$-36.33M$-28.23M$-24.22M$-25.70M$-22.14M
Low Forecast$-14.65M$-14.85M$-36.63M$-50.54M$-31.46M$-17.37M$-9.44M$-18.25M$-5.24M
Surprise %-35.44%-37.19%-14.68%------

CUE Forecast FAQ

Is Cue Biopharma stock a buy?

Cue Biopharma stock has a consensus rating of Buy, based on 3 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Cue Biopharma is a favorable investment for most analysts.

What is Cue Biopharma's price target?

Cue Biopharma's price target, set by 3 Wall Street analysts, averages $4 over the next 12 months. The price target range spans from $4 at the low end to $4 at the high end, suggesting a potential 198.51% change from the previous close price of $1.34.

How does Cue Biopharma stock forecast compare to the average forecast of its sector, industry, and investment themes?

Cue Biopharma stock forecast shows a 198.51% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Cue Biopharma over the past three months?

  • January 2025: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Cue Biopharma’s EPS forecast?

Cue Biopharma's average annual EPS forecast for its fiscal year ending in December is -0.74 for 2024, a -33.33% decrease from the reported $-1.11 in 2023. The prediction for 2025 is $-0.52, $-0.42 for 2026, $-0.46 for 2027, and $-0.24 for 2028.

What is Cue Biopharma’s revenue forecast?

Cue Biopharma's average annual revenue forecast for its fiscal year ending in December is $9.41M for 2024, a 71.40% increase from the reported $5.49M in 2023. The forecast for 2025 is $10.45M, $19.02M for 2026, $19.49M for 2027, and $48.84M for 2028.

What is Cue Biopharma’s net income forecast?

For its fiscal year ending in December, Cue Biopharma's average annual net income forecast is $-33.897M for 2024, reflecting a -33.19% decrease from the reported $-50.733M in 2023. The projection for 2025 is $-22.798M, $-16.833M for 2026, $-21.979M for 2027, and $-11.134M for 2028.